T Therapeutics
Cambridge, GB · 64 employees on LinkedIn · 5 known investors
T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus platform, which identifies antigen-specific human TCRs. The company combines expertise in biopharmaceutical drug development, single cell genomics, machine learning, and structural biology.
Investors · 5
Frequently asked questions
- What does T Therapeutics do?
- T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus platform, which identifies antigen-specific human TCRs. The company combines expertise in biopharmaceutical drug development, single cell genomics, machine learning, and structural biology.
- Who are T Therapeutics's investors?
- T Therapeutics's investors include Cambridge Innovation Capital, F-Prime Capital, Sanofi Ventures, Sofinnova Partners, Digitalis Ventures.
- Where is T Therapeutics headquartered?
- T Therapeutics is headquartered in Cambridge, GB.